Clinical pharmacist directed anticoagulation monitoring services: A prospective interventional study

Abstract

Background and Aims: Antithrombotic therapies are established as cornerstones of treatment for a wide variety of ischemic vascular diseases. The study aimed to develop clinical pharmacist directed anticoagulation monitoring services in the cardiology department at tertiary care referral super specialty hospital. Method: Prospective interventional study was conducted for 12 months in the cardiology inpatient setting of a private tertiary care referral hospital in the Malabar region of Kerala. Constituted to be in three phases, they are: assessment of the present anticoagulation related practices, the development and sharing of anticoagulation protocol and finally the intervention and implementation of the system. Results and Discussion: Monitoring of the treatment could enhance the drug selection approaches, improved adherence to clinical guidelines and health outcomes. Heparin was the commonly prescribed drug in the cardiology department which had the risk of thrombocytopenia and major bleed, whereas this risk was lesser with fondaparinux. Early detection of bleeding could prevent complications from happening to the patients. The collaboration of the clinical pharmacist into anticoagulation therapy influenced the physician to comply with the ACCP guideline. Conclusion: The clinical pharmacist directed anticoagulation monitoring services improved the overall medical status of the patient.

Keywords

• ACCP
• Anticoagulation
• Clinical Pharmacist
• Guideline Compliance
• Management service
• Medication Error

References

1. • Ahmed, I., Majeed, A., & Powell, R. (2007). Heparin induced thrombocytopenia: Diagnosis and management update. Postgraduate Medical Journal, 83(983), 575–582. https://doi.org/10.1136/ pgmj.2007.059188
2. • Akesson, A., Larsson, S. C., Discacciati, A., & Wolk, A. (2014). Lowrisk diet and lifestyle habits in the primary prevention of myocardial infarction in men: A population-based prospective cohort study. Journal of the American College of Cardiology, 64(13), 1299– 1306. https://doi.org/10.1016/j.jacc.2014.06.1190
3. • Bauer, K. A. (2001). Fondaparinux sodium: A selective inhibitor of factor Xa. American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists, 58 Suppl 2, S14-17. https://doi.org/10.1093/ajhp/58.suppl_2.S14
4. • Coussement, P. K., Bassand, J. P., Convens, C., Vrolix, M., Boland, J., Grollier, G., … PENTALYSE investigators. (2001). A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. European Heart Journal, 22(18), 1716–1724. https://doi.org/10.1053/ euhj.2001.2777
5. • Hajj, I., Al-Masri, M., Bashaireh, K., Hani, M. B., Hamouri, S., Khouzami, J., … Fadel, C. (2021). A cross-sectional, multicenter, observational study to assess the prophylaxis of venous thromboembolism in Lebanese and Jordanian hospitals. Thrombosis Journal, 19(1), 9. https://doi.org/10.1186/s12959-021-00261-2
6. • Henriksen, J. N., Nielsen, L. P., Hellebek, A., & Poulsen, B. K. (2017). Medication errors involving anticoagulants: Data from the Danish patient safety database. Pharmacology Research & Perspectives, 5(3), e00307. https://doi.org/10.1002/prp2.307
7. • Kolhatkar, A., Cheng, L., Chan, F. K. I., Harrison, M., & Law, M. R. (2016). The impact of medication reviews by community pharmacists. Journal of the American Pharmacists Association: JAPhA, 56(5), 513-520.e1. https://doi.org/10.1016/j.japh.2016.05.002
8. • Kollias, A., Kyriakoulis, K. G., Dimakakos, E., Poulakou, G., Stergiou, G. S., & Syrigos, K. (2020). Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action. British Journal of Haematology, 189(5), 846–847.

9. • Lakshminarayan, K., Solid, C. A., Collins, A. J., Anderson, D. C., & Herzog, C. A. (2006). Atrial fibrillation and stroke in the general medicare population: A 10-year perspective (1992 to 2002). Stroke, 37(8), 1969–1974. https://doi.org/10.1161/01. STR.0000230607.07928.17
10. • Mamdani, M. M., Racine, E., McCreadie, S., Zimmerman, C., O’Sullivan, T. L., Jensen, G., … Stevenson, J. G. (1999). Clinical and economic effectiveness of an inpatient anticoagulation service. Pharmacotherapy, 19(9), 1064–1074. https://doi.org/10.1592/ phco.19.13.1064.31591
11. • Mosca, L., Barrett-Connor, E., & Wenger, N. K. (2011). Sex/gender differences in cardiovascular disease prevention: What a difference a decade makes. Circulation, 124(19), 2145–2154. https:// doi.org/10.1161/CIRCULATIONAHA.110.968792
12. • Piazza, G., Nguyen, T. N., Cios, D., Labreche, M., Hohlfelder, B., Fanikos, J., … Goldhaber, S. Z. (2011). Anticoagulation-associated adverse drug events. The American Journal of Medicine, 124(12), 1136–1142. https://doi.org/10.1016/j.amjmed.2011.06.009
13. • Pranckeviciene, G., Kadusevicius, E., & Putniene, A. (2013). Influence of coadministration of antithrombotic medicines, warfarin, and NSAIDs on heparin safety: Data from a prospective observational study. Journal of Managed Care Pharmacy: JMCP, 19(6), 478–486. https://doi.org/10.18553/jmcp.2013.19.6.478
14. • Reddy, T., Prasad T S, D., Swetha, S., Nirmala, G., & Ram, P. (2018). A study on antiplatelets and anticoagulants utilisation in a tertiary care hospital. International Journal of Pharmaceutical and Clinical Research, 10, 155–161.
15. • Roberts, L. N., Patel, R. K., & Arya, R. (2009). Venous thromboembolism and ethnicity. British Journal of Haematology, 146(4), 369–383. https://doi.org/10.1111/j.1365-2141.2009.07786.x
16. • Schillig, J., Kaatz, S., Hudson, M., Krol, G. D., Szandzik, E. G., & Kalus, J. S. (2011). Clinical and safety impact of an inpatient pharmacistdirected anticoagulation service. Journal of Hospital Medicine, 6(6), 322–328. https://doi.org/10.1002/jhm.910
17. • Schumock, G. T., Butler, M. G., Meek, P. D., Vermeulen, L. C., Arondekar, B. V., Bauman, J. L., & 2002 Task Force on Economic Evaluation of Clinical Pharmacy Services of the American College of Clinical Pharmacy. (2003). Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy, 23(1), 113–132. https://doi.org/10.1592/phco.23.1.113.31910
18. • Sharma, M., Krishnamurthy, M., Snyder, R., & Mauro, J. (2017). Reducing Error in Anticoagulant Dosing via Multidisciplinary Team Rounding at Point of Care. Clinics and Practice, 7(2), 953. https:// doi.org/10.4081/cp.2017.953
19. • Talon, B., Perez, A., Yan, C., Alobaidi, A., Zhang, K. H., Schultz, B. G., … Touchette, D. R. (2020). Economic evaluations of clinical pharmacy services in the United States: 2011-2017. JACCP: Journal Of The American College of Clinical Pharmacy, 3(4), 793–806. https:// doi.org/10.1002/jac5.1199
20. • Tariq, R. A., Vashisht, R., Sinha, A., & Scherbak, Y. (2021). Medication Dispensing Errors And Prevention. In StatPearls. Treasure Island (FL): StatPearls Publishing. Retrieved from http://www.ncbi.nlm. nih.gov/books/NBK519065/
21. • Thompson, L. E., Maddox, T. M., Lei, L., Grunwald, G. K., Bradley, S. M., Peterson, P. N., … Daugherty, S. L. (2017). Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR®) PINNACLE Registry. Journal of the American Heart Association, 6(7), e005801. https://doi.org/10.1161/JAHA.117.005801
22. • Yau, J. W., Stafford, A. R., Liao, P., Fredenburgh, J. C., Roberts, R., & Weitz, J. I. (2011). Mechanism of catheter thrombosis: Comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. Blood, 118(25), 6667–6674. https:// doi.org/10.1182/blood-2011-07-364141
23. • Yu, H.-T., Dylan, M. L., Lin, J., & Dubois, R. W. (2007). Hospitals’ compliance with prophylaxis guidelines for venous thromboembolism. American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists, 64(1), 69–76. https://doi.org/10.2146/ajhp060115